Streaming Fatigue: 39% Cancel Subscriptions and 55% Join New Services

Our 2023 survey found that a majority of Americans are joining new services while 39% have canceled streaming subscriptions.

2022 International Cancer Education Conference Late-Breaking Abstracts

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial - The Lancet Oncology

Podcast Statistics & Industry Trends 2023: Listens, Gear, & More

WaxBgone Ear Cleaner Earwax Removal Kit, Ear Wax Cleaner, Ear Irrigation Flushing System, Ear Wax Remover Kit, Ear Cleaning Kit & Ear Flush Kit for Adults + (Earwax Removal Drops,

Gen Z Streamers Most Likely to Cancel Subscription Streaming Services

Catheter Ablation of Atrial Fibrillation in Adult Congenital Heart Disease: Procedural Characteristics and Outcomes

Global Streaming Trends 2022: Subscription Fatigue on the Rise

35 Streaming Services Statistics You Need to Know in 2023

35 Streaming Services Statistics You Need to Know in 2023

35 Streaming Services Statistics You Need to Know in 2023

35 Streaming Services Statistics You Need to Know in 2023

HBO's Max Cancels The Most Shows Among Streaming Services, Study Shows

As 'Subscription Fatigue' Sets In, the OTT Reckoning May Be Upon Us

Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial - The Lancet Oncology

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial - The Lancet